EN
instrument_fundamentals
| date | Close | change | Change (%) | instr__open | High | Low |
|---|
instr__news
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | The Manila Times
Truist Lifts BioNTech (BNTX) Price Target After New Partnership
Healthy Returns: AstraZeneca, Pfizer, Gilead release cancer drug data
Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment
BioNTech (NASDAQ:BNTX) Sees Large Volume Increase - Here's Why
BioNTech (NASDAQ:BNTX) Shares Gap Up - Time to Buy?
BioNTech (NASDAQ:BNTX) Given Buy Rating at Truist Financial
Dow Jones Top Company Headlines at 3 AM ET: TSMC Sees Limited Tariff Impact on AI Strength | How ... | Morningstar
Why BioNTech SE (BNTX) Skyrocketed On Monday
Dow Jones Top Company Headlines at 1 AM ET: How Moderna Went From Pandemic Hero to Vaccine Victim | Paramount ... | Morningstar
Dow Jones Top Company Headlines at 11 PM ET: How Moderna Went From Pandemic Hero to Vaccine Victim | Paramount ... | Morningstar
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies
Dow Jones Top Company Headlines at 7 PM ET: Walt Disney Co. to Lay Off Hundreds | Jamie ... | Morningstar
These 10 Stocks Blew Past Expectations
Dow Jones Top Company Headlines at 5 PM ET: Walt Disney Co. to Lay Off Hundreds | Jamie ... | Morningstar
Bristol Myers' cancer deal is promising, but doesn't change our stance on stock yet
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol-Myers and BioNTech: Oncology Collaboration Further Solidifies BNT327's Potential | Morningstar
Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal
Dow Jones Top Company Headlines at 9 AM ET: Campbell's Posts Higher Sales as Consumers Return to Cooking at Home | BioNTech ... | Morningstar
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race | Morningstar
Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (2)
Bristol Myers to help develop cancer drug in BioNTech partnership
BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion | Morningstar
Bristol Myers to Pay $1.5B for BioNTech Cancer Drug Deal | Newsmax.com
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | The Manila Times
Bristol-Myers to Pay BioNTech Up to $11.1 Billion in Cancer Deal
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | Morningstar
BioNTech, Bristol Myers Ink Strategic Partnership To Co-Develop BNT327 For Several Solid Tumor Type
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+ | BioWorld
Wall Street Zen Downgrades BioNTech (NASDAQ:BNTX) to Sell
BioNTech (NASDAQ:BNTX) Shares Gap Down - Time to Sell?
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting | The Manila Times
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, "
AI-Driven mRNA Therapeutics Market Development Accelerated by AI Integration in Drug Design Delivery and Scalable Manufacturing
)
Cambridge R&D Centre being created by BioNTech in £1bn UK spree
2,061 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by GF Fund Management CO. LTD.
BioNTech SE (NASDAQ:BNTX) Stake Cut by Bank of America Corp DE
JPMorgan Chase & Co. Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech's (BNTX) "Buy" Rating Reaffirmed at HC Wainwright
BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Analysts
BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion
BioNTech SE (NASDAQ:BNTX) Shares Sold by Voloridge Investment Management LLC
OMERS ADMINISTRATION Corp Purchases New Holdings in BioNTech SE (NASDAQ:BNTX)
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through | The Manila Times
Tema Etfs LLC Acquires New Shares in BioNTech SE (NASDAQ:BNTX)
Bank of America Securities Keeps Their Buy Rating on BioNTech SE (BNTX) | Markets Insider
Cresset Asset Management LLC Decreases Stock Holdings in BioNTech SE (NASDAQ:BNTX)
BioNTech SE (BNTX): Among the Best Growth Stocks to Buy and Hold for the Long Term
Crestline Management LP Takes $943,000 Position in BioNTech SE (NASDAQ:BNTX)
Fred Alger Management LLC Sells 35,467 Shares of BioNTech SE (NASDAQ:BNTX)
BNP Paribas Financial Markets Takes Position in BioNTech SE (NASDAQ:BNTX)
Morgan Stanley Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (BNTX) Faces Investor Concerns Amid FDA Leadership Shift | BNTX Stock News
BioNTech (NASDAQ:BNTX) Price Target Lowered to $132.00 at Morgan Stanley
BioNTech (BNTX) Stock Declines Amid Leadership Changes and Analyst Downgrade
BioNTech (BNTX) Shares Tumble as FDA Announces Leadership Change
BioNTech (BNTX): Citigroup Maintains Rating, Lowers Price Target | BNTX Stock News
BioNTech SE (NASDAQ:BNTX) Q1 2025 Earnings Call Transcript
Baker BROS. Advisors LP Invests $5.13 Million in BioNTech SE (NASDAQ:BNTX)
BioNTech (BNTX) Target Price Lowered by Citi Analyst Amid Quarte
BioNTech SE (NASDAQ:BNTX) Shares Sold by Axa S.A.
BioNTech news
Latest news
Show more
Morning Note: ECB Rate Cut Expected; Canada PMI in Focus; EUR/USD, USD/CAD
Morning Note: ECB Rate Cut Expected; Broadcom Earnings; Oil Falls on Supply
